{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:52:41Z","timestamp":1792036361365,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T00:00:00Z","timestamp":1567123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-019-3614-y","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T20:01:44Z","timestamp":1567195304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Therapy of nodal Follicular Lymphoma (WHO grade 1\/2) in clinical stage I\/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8402-6694","authenticated-orcid":false,"given":"Laila","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"D\u00fcrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Hohloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meinhard","family":"Kieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Herfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,30]]},"reference":[{"key":"3614_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","volume":"100","author":"L Lowry","year":"2011","unstructured":"Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86\u201392.","journal-title":"Radiother Oncol"},{"key":"3614_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","volume":"156","author":"C McNamara","year":"2012","unstructured":"McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, et al. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol. 2012;156:446\u201367.","journal-title":"Br J Haematol"},{"key":"3614_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/hon.2900120102","volume":"12","author":"G Ganem","year":"1994","unstructured":"Ganem G, Lambin P, Soci\u00e9 G, Girinsky T, Bosq J, Pico JL, et al. Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin\u2019s lymphomas. Hematol Oncol. 1994;12:1\u20138.","journal-title":"Hematol Oncol"},{"key":"3614_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0167-8140(96)01854-3","volume":"42","author":"EJ Sawyer","year":"1997","unstructured":"Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol. 1997;42:49\u201351.","journal-title":"Radiother Oncol"},{"key":"3614_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","volume":"51","author":"T Girinsky","year":"2001","unstructured":"Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys. 2001;51:148\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3614_CR6","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474\u201380.","journal-title":"J Clin Oncol"},{"key":"3614_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","volume":"15","author":"PJ Hoskin","year":"2014","unstructured":"Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15:457\u201363.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3614_CR8","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1007\/s00066-018-1277-3","volume":"194","author":"Laila K\u00f6nig","year":"2018","unstructured":"K\u00f6nig L, H\u00f6rner-Rieber J, Bernhardt D, Hommertgen A, Rieken S, Debus J, Herfarth K. Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas. Strahlenther Onkol. 2018;194(5):454\u201361.","journal-title":"Strahlentherapie und Onkologie"},{"key":"3614_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.ijrobp.2010.06.056","volume":"78","author":"G Ganem","year":"2010","unstructured":"Ganem G, Cartron G, Girinsky T, Haas RL, Cosset JM, Solal-Celigny P. Localized low-dose radiotherapy for follicular lymphoma: history, clinical results, mechanisms of action, and future outlooks. Int J Radiat Oncol Biol Phys. 2010;78:975\u201382.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3614_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","volume":"110","author":"L Knoops","year":"2007","unstructured":"Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood. 2007;110:1116\u201322.","journal-title":"Blood"},{"key":"3614_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.ijrobp.2003.11.017","volume":"59","author":"RL Haas","year":"2004","unstructured":"Haas RL, de Jong D, Vald\u00e9s Olmos RA, Hoefnagel CA, van den Heuvel I, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3614_CR12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1007\/s00066-014-0728-8","volume":"190","author":"K Herfarth","year":"2014","unstructured":"Herfarth K, Konig L. Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study. Strahlenther Onkol. 2014;190:1084\u20135.","journal-title":"Strahlenther Onkol"},{"key":"3614_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/1097-0142(19930401)71:7<2342::AID-CNCR2820710728>3.0.CO;2-I","volume":"71","author":"J Yahalom","year":"1993","unstructured":"Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer. 1993;71:2342\u201350.","journal-title":"Cancer"},{"key":"3614_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/BF02990087","volume":"11","author":"SM Kelsey","year":"1994","unstructured":"Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11:19\u201325.","journal-title":"Med Oncol"},{"key":"3614_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S","volume":"44","author":"TG Landberg","year":"1979","unstructured":"Landberg TG, H\u00e5kansson LG, M\u00f6ller TR, Mattsson WK, Landys KE, Johansson BG, et al. CVP-remission-maintenance in stage I or II non-Hodgkin\u2019s lymphomas: preliminary results of a randomized study. Cancer. 1979;44:831\u20138.","journal-title":"Cancer"},{"key":"3614_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0360-3016(80)90027-9","volume":"6","author":"S Monfardini","year":"1980","unstructured":"Monfardini S, Banfi A, Bonadonna G, Rilke F, Milani F, Valagussa P, et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 1980;6:125\u201334.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 2","key":"3614_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/2.suppl_2.137","volume":"2","author":"P McLaughlin","year":"1991","unstructured":"McLaughlin P, Fuller L, Redman J, Hagemeister F, Durr E, Allen P, et al. Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann Oncol. 1991;2(Suppl 2):137\u201340.","journal-title":"Ann Oncol"},{"key":"3614_CR18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","volume":"21","author":"JF Seymour","year":"2003","unstructured":"Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21:2115\u201322.","journal-title":"J Clin Oncol"},{"key":"3614_CR19","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","volume":"15","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266\u201374.","journal-title":"J Clin Oncol"},{"key":"3614_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1269\/jrr.47.183","volume":"47","author":"I Skvortsova","year":"2006","unstructured":"Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin\u2019s lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res. 2006;47:183\u201396.","journal-title":"J Radiat Res"},{"key":"3614_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet"},{"key":"3614_CR22","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1200\/JCO.2018.77.9892","volume":"36","author":"M MacManus","year":"2018","unstructured":"MacManus M, Fisher R, Roos D, O\u2019Brien P, Macann A, Davis S, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03. J Clin Oncol. 2018;36:2918\u201325.","journal-title":"J Clin Oncol"},{"key":"3614_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2407-11-87","volume":"11","author":"M Witzens-Harig","year":"2011","unstructured":"Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer. 2011;11:87.","journal-title":"BMC Cancer"},{"key":"3614_CR24","doi-asserted-by":"crossref","unstructured":"Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich H-T, Witzens-Harig M, Hess CF, Dorken B, Durig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M. Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. HemaSphere. 2018;2(6):e160.","DOI":"10.1097\/HS9.0000000000000160"},{"key":"3614_CR25","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"GA Salles","year":"2013","unstructured":"Salles GA, Morschhauser F, Solal-C\u00e9ligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31:2920\u20136.","journal-title":"J Clin Oncol"},{"key":"3614_CR26","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","volume":"33","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015;33:3467\u201374.","journal-title":"J Clin Oncol"},{"key":"3614_CR27","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"3614_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442\u20137.","journal-title":"Ann Oncol"},{"key":"3614_CR29","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","volume":"101","author":"R Elstrom","year":"2003","unstructured":"Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875\u20136.","journal-title":"Blood"},{"key":"3614_CR30","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/cncr.22807","volume":"110","author":"N Tsukamoto","year":"2007","unstructured":"Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652\u20139.","journal-title":"Cancer"},{"key":"3614_CR31","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/annonc\/mdl014","volume":"17","author":"S W\u00f6hrer","year":"2006","unstructured":"W\u00f6hrer S, Jaeger U, Kletter K, Becherer A, Hauswirth A, Turetschek K, et al. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. Ann Oncol. 2006;17:780\u20134.","journal-title":"Ann Oncol"},{"key":"3614_CR32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","volume":"24","author":"S Luminari","year":"2013","unstructured":"Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108\u201312.","journal-title":"Ann Oncol"},{"key":"3614_CR33","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, M\u00fceller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048\u201358.","journal-title":"J Clin Oncol"},{"key":"3614_CR34","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"3614_CR35","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-019-3614-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-019-3614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T23:13:53Z","timestamp":1598656433000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-019-3614-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1186\/s13063-019-3614-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,30]]},"assertion":[{"value":"7 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Heidelberg Ethics Committee approved this study on June 6, 2016 (AFmu-316\/2017). Consent to participate\/informed consent will be obtained from all participants in the study.Central ethical approval has been confirmed from the Heidelberg Ethics Committee (reference approval number: AFmu-316\/2017) and we will not begin recruiting at other centers in the trial until local ethical approval has been obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"544"}}